Candel Therapeutics (CADL) 2025 Conference Transcript

Summary of Candel Therapeutics Conference Call Company Overview - Candel Therapeutics is focused on developing viral immunotherapies for difficult-to-treat cancers, with a lead compound named CAN2409, which is an adenovirus engineered to deliver a gene encoding thymidine kinase into tumor cells [2][6] Core Points and Arguments Lead Product: CAN2409 - CAN2409 is designed to induce immunogenic cell death, allowing the immune system to recognize tumor-specific antigens [6][7] - The compound has been administered to over 1,000 patients, demonstrating safety and tolerability [8] - Fast track designations have been received for prostate cancer, pancreatic cancer, and non-small cell lung cancer, along with orphan drug designation for pancreatic cancer [8] Clinical Trial Results - A pivotal phase three trial showed that CAN2409 plus valacyclovir improved disease-free survival by 30% compared to placebo [16][42] - The trial involved 745 patients, focusing on early localized non-metastatic prostate cancer, a significant area of unmet need [17][12] - The treatment demonstrated a 38% improvement in prostate cancer-specific disease-free survival [30][42] - A high percentage (over 80%) of patients achieved a pathological complete response in a two-year biopsy [39][42] Safety and Tolerability - The treatment was well tolerated, with mild flu-like symptoms reported, comparable to COVID-19 vaccination [25][26] - There were trends towards lower serious adverse events in the treatment group compared to placebo [26] Future Plans and Market Strategy - Candel Therapeutics is preparing for a Biologics License Application (BLA) submission expected in Q4 of the following year [42] - The company is working with external partners for manufacturing and market research to ensure a successful launch [45][46] - Pricing strategy is being developed to ensure broad patient access, with benchmarks for advanced disease treatments ranging from $130,000 to $260,000 [50] Other Important Content Additional Indications - Encouraging data were presented for CAN2409 in borderline resectable pancreatic cancer, showing a median overall survival of 31.4 months compared to 12.5 months in the control group [54] - Data for therapy-resistant non-small cell lung cancer indicated a median overall survival of 25.4 months, which is better than existing treatments [59] Research and Development Pipeline - Candel Therapeutics is also developing CAM310, a next-generation HSV oncolytic virus for recurrent glioblastoma, with promising results expected [61] Team and Governance - The company has a senior team with extensive experience in drug discovery and development, supported by a research advisory board of notable experts in oncology [62] This summary encapsulates the key points from the conference call, highlighting the company's focus on innovative cancer therapies, promising clinical results, and strategic plans for market entry.